Pulsenmore Ltd. completed the CE European registration for Pulsenmore FC, a home ultrasound system designed for follicular monitoring during IVF and fertility preservation treatments. This regulatory approval under the European Medical Device Regulation enables the company to market and sell the device across European markets, marking its second product authorized in Europe and its first expansion beyond prenatal care into the broader women's health sector. The filing highlights a prior commercial agreement with Clalit Health Services in Israel and clinical study results demonstrating high agreement between home and in-clinic scans. Pulsenmore Ltd. is a healthcare technology company developing self-use ultrasound solutions for remote patient monitoring.

Pulsenmore Ltd. reported financial results for the six months ended June 30, 2026, showing revenues of NIS 6.1 million ($2.0 million), a 53% increase year-over-year, driven by higher sales to Clalit Health Services and revenue from Pulsenmore FC units. The company recorded an operating loss of NIS 20.8 million ($7.0 million) and a net comprehensive loss of NIS 35.1 million ($11.8 million). Financial results were significantly impacted by non-cash expenses related to a June 26, 2026 private placement of pre-funded warrants and ordinary warrants, which generated gross proceeds of approximately $7.5 million. The company also received additional grants from the Israel Innovation Authority for AI programs. Pulsenmore Ltd. is an Israeli healthcare technology company that develops portable ultrasound devices for home use.

On August 19, 2026, Pulsenmore Ltd. announced that Lis Maternity and Women’s Hospital at Ichilov has adopted its home ultrasound technology for pregnancy monitoring. This integration expands the company's presence in central Israel and broadens access to a hybrid monitoring model that combines hospital-based care with at-home scans under medical guidance. The adoption adds to Pulsenmore's existing Israeli operations, which include a nationwide service supported by Clalit Health Services and Hospital at Home models implemented at several other facilities. This development signifies continued commercial expansion of its remote maternal health solutions within the Israeli healthcare system. Pulsenmore Ltd. operates in the digital health industry, developing home-use ultrasound technology for remote prenatal care.

Pulsenmore Ltd. announced that the Israel Innovation Authority approved a $1.27 million grant for its SmartScan AI research and development program on August 17, 2026. This funding supports a 12-month initiative to develop AI-powered real-time ultrasound analysis and dynamic guidance to reduce operator dependency in home scans. The approval marks the second AI grant received within one month, bringing total recent support to approximately $1.6 million for programs with a combined scope of $3.12 million. Pulsenmore operates in the medical technology industry, specializing in home-use ultrasound devices for maternal health.

On July 13, 2026, Pulsenmore Ltd. announced its selection for an Israel Innovation Authority and Ministry of Health program to lead a $1 million AI development project. Pulsenmore Ltd. is a medical technology company specializing in remote patient monitoring.